Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 283

1.

s-SHIP expression identifies a subset of murine basal prostate cells as neonatal stem cells.

Brocqueville G, Chmelar RS, Bauderlique-Le Roy H, Deruy E, Tian L, Vessella RL, Greenberg NM, Rohrschneider LR, Bourette RP.

Oncotarget. 2016 Apr 12. doi: 10.18632/oncotarget.8709. [Epub ahead of print]

2.

Amplification of the 9p13.3 chromosomal region in prostate cancer.

Latonen L, Leinonen KA, Grönlund T, Vessella RL, Tammela TL, Saramäki OR, Visakorpi T.

Genes Chromosomes Cancer. 2016 Aug;55(8):617-25. doi: 10.1002/gcc.22364. Epub 2016 May 2.

PMID:
27074291
3.

Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.

Zhao Y, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J, Karnes RJ, Tindall DJ, Kim Y, MacLeod R, Ekker SC, Kang T, Sun Y, Huang H.

Cell Rep. 2016 Apr 19;15(3):599-610. doi: 10.1016/j.celrep.2016.03.038. Epub 2016 Apr 7.

4.

Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.

Roudier MP, Winters BR, Coleman I, Lam HM, Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B, Lange PH, Snyder LA, Srivastava S, Corey E, Vessella RL, Nelson PS, Üren A, Morrissey C.

Prostate. 2016 Jun;76(9):810-22. doi: 10.1002/pros.23171. Epub 2016 Mar 16.

PMID:
26990456
5.

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.

Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, DeSarkar N, Higano C, Yu EY, Coleman R, Schultz N, Fang M, Lange PH, Shendure J, Vessella RL, Nelson PS.

Nat Med. 2016 Apr;22(4):369-78. doi: 10.1038/nm.4053. Epub 2016 Feb 29.

PMID:
26928463
6.

Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming.

Borges GT, Vêncio EF, Quek SI, Chen A, Salvanha DM, Vêncio RZ, Nguyen HM, Vessella RL, Cavanaugh C, Ware CB, Troisch P, Liu AY.

J Cell Physiol. 2016 Sep;231(9):2040-7. doi: 10.1002/jcp.25313. Epub 2016 Feb 4.

PMID:
26773436
7.

Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.

Haider M, Zhang X, Coleman I, Ericson N, True LD, Lam HM, Brown LG, Ketchanji M, Nghiem B, Lakely B, Coleman R, Montgomery B, Lange PH, Roudier M, Higano CS, Bielas JH, Nelson PS, Vessella RL, Morrissey C.

Clin Exp Metastasis. 2016 Mar;33(3):239-48. doi: 10.1007/s10585-015-9773-7. Epub 2015 Dec 14.

PMID:
26667932
8.

High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer.

Wu Y, Schoenborn JR, Morrissey C, Xia J, Larson S, Brown LG, Qu X, Lange PH, Nelson PS, Vessella RL, Fang M.

J Mol Diagn. 2016 Jan;18(1):131-43. doi: 10.1016/j.jmoldx.2015.08.004. Epub 2015 Nov 20.

PMID:
26607774
9.

Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.

DiPippo VA, Nguyen HM, Brown LG, Olson WC, Vessella RL, Corey E.

Prostate. 2016 Feb 15;76(3):325-34. doi: 10.1002/pros.23124. Epub 2015 Nov 20.

PMID:
26585210
10.

The biology and clinical implications of prostate cancer dormancy and metastasis.

Morrissey C, Vessella RL, Lange PH, Lam HM.

J Mol Med (Berl). 2016 Mar;94(3):259-65. doi: 10.1007/s00109-015-1353-4. Epub 2015 Oct 21. Review.

PMID:
26489605
11.

Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.

Tsai H, Morais CL, Alshalalfa M, Tan HL, Haddad Z, Hicks J, Gupta N, Epstein JI, Netto GJ, Isaacs WB, Luo J, Mehra R, Vessella RL, Karnes RJ, Schaeffer EM, Davicioni E, De Marzo AM, Lotan TL.

Clin Cancer Res. 2015 Dec 15;21(24):5619-29. doi: 10.1158/1078-0432.CCR-15-0744. Epub 2015 Aug 5.

PMID:
26246306
12.

Epigenetically altered miR-193b targets cyclin D1 in prostate cancer.

Kaukoniemi KM, Rauhala HE, Scaravilli M, Latonen L, Annala M, Vessella RL, Nykter M, Tammela TL, Visakorpi T.

Cancer Med. 2015 Sep;4(9):1417-25. doi: 10.1002/cam4.486. Epub 2015 Jul 1.

13.

Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.

Ruppender N, Larson S, Lakely B, Kollath L, Brown L, Coleman I, Coleman R, Nguyen H, Nelson PS, Corey E, Snyder LA, Vessella RL, Morrissey C, Lam HM.

PLoS One. 2015 Jun 19;10(6):e0130565. doi: 10.1371/journal.pone.0130565. eCollection 2015.

14.

SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.

Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, Lam HM, Dumpit R, Corey E, Chéry L, Lakely B, Higano CS, Montgomery B, Roudier M, Lange PH, Nelson PS, Vessella RL, Morrissey C.

Clin Cancer Res. 2015 Oct 15;21(20):4698-708. doi: 10.1158/1078-0432.CCR-15-0157. Epub 2015 Jun 12.

PMID:
26071481
15.

Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.

Annala M, Kivinummi K, Tuominen J, Karakurt S, Granberg K, Latonen L, Ylipää A, Sjöblom L, Ruusuvuori P, Saramäki O, Kaukoniemi KM, Yli-Harja O, Vessella RL, Tammela TL, Zhang W, Visakorpi T, Nykter M.

Oncotarget. 2015 Mar 20;6(8):6235-50.

16.

CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.

Ishikura N, Kawata H, Nishimoto A, Nakamura R, Tsunenari T, Watanabe M, Tachibana K, Shiraishi T, Yoshino H, Honma A, Emura T, Ohta M, Nakagawa T, Houjo T, Corey E, Vessella RL, Aoki Y, Sato H.

Int J Oncol. 2015 Apr;46(4):1560-72. doi: 10.3892/ijo.2015.2860. Epub 2015 Jan 30.

PMID:
25634071
17.

Reprogramming of prostate cancer cells--technical challenges.

Borges GT, Vêncio EF, Vêncio RZ, Vessella RL, Ware CB, Liu AY.

Curr Urol Rep. 2015 Jan;16(1):468. doi: 10.1007/s11934-014-0468-4. Review.

PMID:
25404182
18.

Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.

Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E, Higano CS, Matsumoto AM, Montgomery RB, Nelson PS.

PLoS One. 2014 Oct 30;9(10):e111545. doi: 10.1371/journal.pone.0111545. eCollection 2014.

19.

Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.

DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E.

Prostate. 2015 Feb 15;75(3):303-13. doi: 10.1002/pros.22916. Epub 2014 Oct 18.

PMID:
25327986
20.

Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways.

Chéry L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, Montgomery B, Lange P, Snyder LA, Vessella RL, Morrissey C.

Oncotarget. 2014 Oct 30;5(20):9939-51.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk